MMJ International Holdings Corp is preparing a lawsuit against the Drug Enforcement Administration (DEA) claiming the agency is violating the law by not responding to its application to grow pharmaceutical cannabis to support its research. MMJ, which has two Food and Drug Administration (FDA) investigational drug applications to research its developed soft gelatin capsule in clinical trials for multiple sclerosis and Huntington’s disease, filed its application nearly five years ago. MMJ alleges that the DEA’s inaction on its application is in violation of the Controlled Substance Act (CSA) and the Marijuana and Cannabidiol Research Expansion Act (MCREA), which was signed into law in December 2022.
Late last month, Megan Sheehan of Sheehan & Associates, representing MMJ, sent a warning letter to DEA Deputy Assistant Administrator Matthew Strait, and DEA regulatory chief Ricardo Quintero, informing them that they were in violation of the law.
Read full report at
https://www.ganjapreneur.com/cannabis-research-company-planning-lawsuit-against-dea-for-failure-to-follow-federal-law/
